Skip to main content
Top
Published in: BMC Nephrology 1/2015

Open Access 01-12-2015 | Research article

Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities

Authors: Louise Schilder, S. Azam Nurmohamed, Pieter M. ter Wee, Nanne J. Paauw, Armand RJ Girbes, Albertus Beishuizen, Robert HJ Beelen, AB Johan Groeneveld

Published in: BMC Nephrology | Issue 1/2015

Login to get access

Abstract

Background

Novel putative mediators of acute kidney injury (AKI) include immune-cell derived tumour necrosis factor-like weak inducer of apoptosis (TWEAK), angiopoietin-2 (Ang-2) and protein pentraxin-3 (PTX3). The effect of continuous venovenous hemofiltration (CVVH) and different anticoagulation regimens on plasma levels were studied.

Methods

At 0, 10, 60, 180 and 720 min of CVVH, samples were collected from pre- and postfilter blood and ultrafiltrate. No anticoagulation (n = 13), unfractionated heparin (n = 8) or trisodium citrate (n = 21) were compared.

Results

Concentrations of TWEAK, Ang-2 and PTX3 were hardly affected by CVVH since the mediators were not (TWEAK, PTX3) or hardly (Ang-2) detectable in ultrafiltrate, indicating negligible clearance by the filter in spite of molecular sizes (TWEAK, PTX3) at or below the cutoff of the membrane. Heparin use, however, was associated with an increase in in- and outlet plasma TWEAK.

Conclusion

Novel AKI mediators are not cleared nor produced by CVVH. However, heparin anticoagulation increased TWEAK levels in patient’s plasma whereas citrate did not, favouring the latter as anticoagulant in CVVH for AKI.
Literature
1.
go back to reference Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–8.CrossRefPubMed Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–8.CrossRefPubMed
2.
go back to reference Sanz AB, Sanchez-Nino MD, Ortiz A. TWEAK, a multifunctional cytokine in kidney injury. Kidney Int. 2011;80:708–18.CrossRefPubMed Sanz AB, Sanchez-Nino MD, Ortiz A. TWEAK, a multifunctional cytokine in kidney injury. Kidney Int. 2011;80:708–18.CrossRefPubMed
3.
go back to reference Hotta K, Sho M, Yamato I, Shimada K, Harada H, Akahori T, et al. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int. 2011;79:179–88.CrossRefPubMed Hotta K, Sho M, Yamato I, Shimada K, Harada H, Akahori T, et al. Direct targeting of fibroblast growth factor-inducible 14 protein protects against renal ischemia reperfusion injury. Kidney Int. 2011;79:179–88.CrossRefPubMed
4.
go back to reference Kümpers P, Hafer C, David S, Hecker H, Lukasz A, Fliser D, et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med. 2010;36:462–70.CrossRefPubMed Kümpers P, Hafer C, David S, Hecker H, Lukasz A, Fliser D, et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med. 2010;36:462–70.CrossRefPubMed
5.
go back to reference Molema G, Zijlstra JG, Struys MM, Heeringa P, Houwertjes MC, Jongman RM, et al. Age-dependent role of microvascular endothelial and polymorphonuclear cells in lipopolysaccharide-induced acute kidney injury. Anesthesiology. 2012;117:126–36.CrossRefPubMed Molema G, Zijlstra JG, Struys MM, Heeringa P, Houwertjes MC, Jongman RM, et al. Age-dependent role of microvascular endothelial and polymorphonuclear cells in lipopolysaccharide-induced acute kidney injury. Anesthesiology. 2012;117:126–36.CrossRefPubMed
6.
go back to reference Liu KL, Lee KT, Chang CH, Chen YC, Lin SM, Chu PH. Elevated plasma thrombomodulin and angiopoietin-2 predict the development of acute kidney injury in patients with acute myocardial infarction. Crit Care. 2014;18:R100.CrossRefPubMedPubMedCentral Liu KL, Lee KT, Chang CH, Chen YC, Lin SM, Chu PH. Elevated plasma thrombomodulin and angiopoietin-2 predict the development of acute kidney injury in patients with acute myocardial infarction. Crit Care. 2014;18:R100.CrossRefPubMedPubMedCentral
7.
8.
go back to reference Lech M, Römmele C, Gröbmayr R, Susanti HE, Kulkarni OP, Wang S, et al. Endogenous and exogenous pentraxin-3 limits postischemic acute and chronic kidney injury. Kidney Int. 2013;83:647–61.CrossRefPubMed Lech M, Römmele C, Gröbmayr R, Susanti HE, Kulkarni OP, Wang S, et al. Endogenous and exogenous pentraxin-3 limits postischemic acute and chronic kidney injury. Kidney Int. 2013;83:647–61.CrossRefPubMed
9.
go back to reference Tiranathanagul K, Jearnsujitwimol O, Susantitaphong P, Kijkriengkraikul N, Leelahavanichkul A, Srisawat N, et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Ther Apher Dial. 2011;15:556–64.CrossRefPubMed Tiranathanagul K, Jearnsujitwimol O, Susantitaphong P, Kijkriengkraikul N, Leelahavanichkul A, Srisawat N, et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Ther Apher Dial. 2011;15:556–64.CrossRefPubMed
10.
go back to reference Schilder L, Nurmohamed SA, ter Wee PM, Paauw NJ, Girbes AR, Beishuizen A, et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol. 2014;15:9.CrossRef Schilder L, Nurmohamed SA, ter Wee PM, Paauw NJ, Girbes AR, Beishuizen A, et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol. 2014;15:9.CrossRef
11.
go back to reference Schilder L, Nurmohamed SA, Ter Wee PM, Girbes AR, Beishuizen A, Paauw NJ, et al. Effect of anticoagulation regimens on handling of interleukin-6 and −8 during continuous venovenous hemofiltration in critically ill patients with acute kidney injury. Cytokine. 2012;60:601–7.CrossRefPubMed Schilder L, Nurmohamed SA, Ter Wee PM, Girbes AR, Beishuizen A, Paauw NJ, et al. Effect of anticoagulation regimens on handling of interleukin-6 and −8 during continuous venovenous hemofiltration in critically ill patients with acute kidney injury. Cytokine. 2012;60:601–7.CrossRefPubMed
12.
go back to reference Nurmohamed SA, Vervloet MG, Girbes AR, Ter Wee PM, Groeneveld AB. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study. Blood Purif. 2007;25:316–23.CrossRefPubMed Nurmohamed SA, Vervloet MG, Girbes AR, Ter Wee PM, Groeneveld AB. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study. Blood Purif. 2007;25:316–23.CrossRefPubMed
13.
go back to reference Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, et al. CASH study group: Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury a multi-center randomized clinical trial. Crit Care. 2014;18:472.CrossRefPubMedPubMedCentral Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, et al. CASH study group: Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury a multi-center randomized clinical trial. Crit Care. 2014;18:472.CrossRefPubMedPubMedCentral
14.
15.
go back to reference Lukasz A, Hellpap J, Horn R, Kielstein JT, David S, Haller H, et al. Circulating angiopoietin-1 and angiopoietin-1 in critically ill patients: development and clinical application of two new immunoassays. Crit Care. 2008;12:R94.CrossRefPubMedPubMedCentral Lukasz A, Hellpap J, Horn R, Kielstein JT, David S, Haller H, et al. Circulating angiopoietin-1 and angiopoietin-1 in critically ill patients: development and clinical application of two new immunoassays. Crit Care. 2008;12:R94.CrossRefPubMedPubMedCentral
16.
go back to reference Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009;47:471–7.CrossRefPubMed Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med. 2009;47:471–7.CrossRefPubMed
17.
go back to reference Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37:545–52.CrossRefPubMed Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37:545–52.CrossRefPubMed
18.
go back to reference Hochart H, Jenkins PV, Preston RJ, Smith OP, White B, O’Donnell J. Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood. Thromb Haemost. 2008;99:570–5.PubMed Hochart H, Jenkins PV, Preston RJ, Smith OP, White B, O’Donnell J. Concentration-dependent roles for heparin in modifying lipopolysaccharide-induced activation of mononuclear cells in whole blood. Thromb Haemost. 2008;99:570–5.PubMed
19.
go back to reference Meyer T, Amaya M, Desai H, Robles-Carrillo L, Hatfield M, Francis JL, et al. Human platelets contain and release TWEAK. Platelets. 2010;21:571–4.CrossRefPubMed Meyer T, Amaya M, Desai H, Robles-Carrillo L, Hatfield M, Francis JL, et al. Human platelets contain and release TWEAK. Platelets. 2010;21:571–4.CrossRefPubMed
21.
go back to reference Yamamoto T, Nascimento MM, Hayashi SY, Qureshi AR, Waniewski J, Brodin LÅ, et al. Changes in circulating biomarkers during a single hemodialysis session. Hemodial Int. 2013;17:59–66.CrossRefPubMed Yamamoto T, Nascimento MM, Hayashi SY, Qureshi AR, Waniewski J, Brodin LÅ, et al. Changes in circulating biomarkers during a single hemodialysis session. Hemodial Int. 2013;17:59–66.CrossRefPubMed
Metadata
Title
Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities
Authors
Louise Schilder
S. Azam Nurmohamed
Pieter M. ter Wee
Nanne J. Paauw
Armand RJ Girbes
Albertus Beishuizen
Robert HJ Beelen
AB Johan Groeneveld
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2015
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-015-0167-5

Other articles of this Issue 1/2015

BMC Nephrology 1/2015 Go to the issue